24-Week Real-World Effectiveness and Safety of Lebrikizumab for Atopic Dermatitis in Japan: An Analysis Stratified by Prior Systemic Therapy
Bibliographic record
Abstract
Abstract: Background: The data are limited on the real-world effectiveness of an anti-interleukin (IL)-13 monoclonal antibody lebrikizumab for atopic dermatitis (AD). Objective: To evaluate the 24-week real-world effectiveness of lebrikizumab in Japanese patients with AD, stratified by the presence or absence of prior systemic therapy. Methods: We conducted a multicenter, prospective study of 134 Japanese AD patients treated with lebrikizumab. We evaluated clinical outcomes throughout a 24-week period in patients with or without prior systemic therapy. Results: Among lebrikizumab-treated patients, eczema area and severity index (EASI) and scores of patient-reported outcomes (peak pruritus numerical rating scale, sleep quality numerical rating scale, AD control tool, dermatology life quality index, and patient-oriented eczema measure) rapidly decreased until week 12, and these improvements persisted until week 24. At week 24, the achievement rates of EASI 75, EASI 90, and investigator’s global assessment 0/1 in systemic therapy-naïve patients were 75.6%, 58.5%, and 43.5%, respectively, which were higher than those in systemic therapy-experienced patients, 55.5%, 22.2%, and 26.9%, respectively. There were no serious treatment-emergent adverse events until week 24. Conclusion: Lebrikizumab treatment provided favorable effectiveness and tolerability for AD in real-world practice, with slightly higher effectiveness in systemic therapy-naïve patients compared to therapy-experienced patients.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.000 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".